Real World Evidence for COVID-19:
Making an impact now and into the future

Date: Wednesday, March 31, 12:00pm – 1:00pm EDT

During this not-to-miss webinar, IQVIA experts will provide a detailed look into various types of real world data (RWD) sources and how they are being used to strengthen insights about COVID-19, including its effects on people who are infected but not hospitalized.

The virtual event will examine how questions such as the following, can be addressed efficiently:

• How can I better understand COVID-19 symptoms and severity, and the progression of the virus outside of the hospital, especially in terms of both short- and longer-term effects?
• In the community setting, what symptoms best distinguish those who tested positive for COVID-19 from those who tested negative?
• What treatments are people using to combat COVID-19 symptoms (prescriptions, OTC, herbs), and which, if any, are effective?
• What are the emerging predominant characteristics of long COVID-19?
• Among those reporting a positive COVID-19 test, are there meaningful differences in the severity and duration of symptoms by race, use of specific medications, or other characteristics?
• How are people responding to the COVID-19 vaccine in terms of signs and symptoms experienced after vaccination, and how can we understand if and how people are benefitting from being vaccinated?
• What approaches can we use to find out about special sub-populations of interest (e.g., pregnancy, various ethnicities, co-morbidities)?
• Do studies based on person-generated health data work and what are the pitfalls to watch for?
• How do you use findings from "citizen science" to drive any of the research on COVID-19?

By attending this engaging session, you’ll learn about IQVIA’s COVID Active Research Experience (CARE) Project, as well as approaches to utilizing and the benefits of person-generated health data, and how that data can be
strengthened by linkage with secondary data. The session will examine key attributes of the data, strengths, limitations, and uses for addressing questions of interest to patients, care providers, health systems, and payers, as well as other key stakeholders.;

After attending this engaging session, you will:

• Better understand the various RWD sources and how they have and will continue to be used to understand COVID-19 in the near-term and longer
• Uncover strategic approaches to linking various data sources such as that from patient reported registries and secondary data sources for meaningful insights
• Recognize the current and growing role and value that patient-generated data provides and how it can fit into your study design

We hope to see you on March 31! And if you can’t attend live, register and the on-demand version will be sent to you following the webinar.

Panelists:

	Nancy A. Dreyer, MPH, PhD, FISPE Chief Scientific Officer and Senior VP for Real World Solutions at IQVIA As the Chief Scientific Officer and Senior Vice President for Real World Solutions at IQVIA, Nancy Dreyer’s current work is focused on COVID-19, including understanding the natural history, risk factors, and the risks and benefits of various medications and vitamin supplements, as well as working with professional sports leagues to support safe return to play. She brings over 30 years of industry experience to her role. Dr. Dreyer earned her PhD and MPH with a concentration in epidemiology from the University of North Carolina at Chapel Hill.
	Matthew W. Reynolds, PhD, FISPE Vice President, Real World Evidence at IQVIA As the VP of Real World Evidence at IQVIA, Dr. Matthew Reynolds leads the conceptualization, selling, and execution of studies that use real world data, including innovative study designs that include primary data collection. He works closely with Nancy Dreyer, leading COVID-19 real-world research activities. Additionally, Dr. Reynolds provides senior pharmacoepidemiology internal and external thought leadership for individual projects and broader team/company strategic direction, while developing relationships with key internal and external stakeholders to assure and expand IQVIA scientific business. Dr. Reynolds earned his graduate and doctoral degrees in epidemiology and preventive medicine from the University of Maryland at Baltimore in January 2000.